Dominant mutations in the T-box transcription factor gene TBX5 cause Holt-Oram syndrome (HOS), an inherited human disease characterized by upper limb malformations and congenital heart defects (CHDs) of variable severity. We hypothesize that minor alterations in the dosage of Tbx5 directly influences severity of CHDs. Using a mouse allelic series, we show a sensitive inverse correlation between Tbx5 dosage and abnormal cardiac morphogenesis and gene expression. The CHDs found in mice harbouring a hypomorphic allele of Tbx5 (Tbx5 lox/+ mice) are less pronounced than those found in Tbx5 haploinsufficient mice (Tbx5 del/+ ), and homozygous hypomorphic (Tbx5 lox/lox ) embryos have noticeably more advanced cardiac development than Tbx5 null (Tbx5 del/del ) embryos. Examination of target gene expression across the allelic series uncovers very fine sensitivity across the range of Tbx5 dosages, in which some genes respond dramatically differently to only 15% differences in Tbx5 mRNA levels. This analysis was expanded to a genome-wide level, which uncovered a Tbx5 dosage-sensitive genetic program involving a network of cardiac transcription factors, developmentally important cell-cell signaling molecules, and ion channel proteins. These results indicate an exquisite sensitivity of the developing heart to Tbx5 dosage and provide significant insight into the transcriptional and cellular mechanisms that are disrupted in CHDs.
Introduction
Cardiogenesis requires the coordinated development of many unique groups of cells that must precisely come together to form the elements that make up the adult heart. Such synchronicity is directed by precise patterns of gene expression that communicate information to cardiac precursors about the state of heart development, as well as their location with respect to other cells. Spatial and temporal information is ultimately communicated to the nucleus of developing heart cells by activation of specific sets of cardiac transcription factors (reviewed by Bruneau, 2002; Moorman et al., 2004; Mori and Bruneau, 2004; Srivastava and Olson, 2000) .
Changes in the functional concentration of cardiac transcription factor proteins, due to dominant mutations in one allele (haploinsufficiency), can result in congenital heart defects (CHDs) in humans (Bruneau, 2002; Epstein and Buck, 2000; Gruber and Epstein, 2004) . The CHDs associated with DiGeorge Syndrome (OMIM #188400) and Holt-Oram syndrome (OMIM #142900) are caused by dominant mutations in the T-box transcription factor genes TBX1 (Jerome and Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001; Yagi et al., 2003) and TBX5 (Basson et al., 1997; Li et al., 1997; Mori and Bruneau, 2004) , respectively. In addition, non-syndromic CHDs have been reported in families with dominant mutations in the homeobox transcription factor gene NKX2-5 (Benson et al., 1999; Schott et al., 1998) and zincfinger transcription factor gene GATA4 (Garg et al., 2003; Okubo et al., 2004) .
Work conducted to date examining the mechanistic basis behind Holt-Oram syndrome (HOS) has focused on describing the genetic and phenotypic changes resulting from Tbx5 haploinsufficiency (Basson et al., 1997; Bruneau et al., 2001; Li et al., 1997; Mori and Bruneau, 2004 , and references therein). However, examination of phenotype is complicated by large variations in CHD severity of HOS clinical presentation, even between members of the same family. Attempts to correlate mutations in TBX5 with severity of HOS manifestation have yielded mixed results but generally suggest that genetic modifiers influence CHD severity more than environmental or genotypic differences (Basson et al., 1999; Brassington et al., 2003; Huang et al., 2002) .
Cis-regulatory modules frequently contain multiple sites for a single transcription factor (Davidson, 2002; Markstein et al., 2004) and required occupancy of multiple independent DNAbinding interactions would confer increased dosage sensitivity . Indeed, Nppa and Gja5, genes sensitive to Tbx5 dosage in mouse, have several Tbx binding sites in their regulatory regions (Bruneau et al., 2001 , and unpublished data). We hypothesized that subtle alterations in Tbx5 dosage due to underlying genetic and/or environmental conditions may account for the variation in HOS manifestation and by extension that genes most sensitive to dosage would be altered in all HOS patients, whereas others would only show changes in a subset of severe cases. Understanding which genes are most sensitive to Tbx5 dosage and therefore most likely altered in the diseased state would be an important step in understanding and treating CHDs caused by transcription factor haploinsufficiency.
Tbx5 heterozygous null (Tbx5 del/+ ) mice recapitulate the CHDs seen in HOS patients whereas homozygous null mice (Tbx5 del/del ) are growth arrested at E9.0 and die in utero by E10.5 due to severe heart defects (Bruneau et al., 2001 ). Here we show that the conditional allele (Tbx5 lox )-which was a precursor to the Cre-induced null allele-is hypomorphic, thus creating an allelic series based on dosage of Tbx5. Hypomorphic mutants exhibit milder defects than the respective null mutants, both in the heterozygous state as models of HOS, and as homozygous embryos with defective cardiac morphogenesis. Furthermore, we show that increases in CHD severity are linked to differential changes in expression of downstream targets of Tbx5. By gene expression profiling, we identify genes with variable sensitivity to Tbx5 dosage and determine that Tbx5 is likely to regulate complex transcriptional networks. The exquisite sensitivity of downstream genes to Tbx5 dosage provides a mechanistic explanation for the large differences in HOS clinical presentation; the identified targets provide an entry point to understanding the complex phenotypes caused by Tbx5 haploinsufficiency.
Materials and methods

Animals Tbx5
lox/+ and Tbx5 del/+ mice were generated and genotyped as previously described (Bruneau et al., 2001) . For removal of the Neo r gene, Tbx5 lox/+ mice were bred to EIIaCre mice (129SvJ strain; Jackson Laboratories, Bar Harbour, ME) and genotyped for the presence of Tbx5 exon 3 and the absence of Neo r using PCR. The EIIaCre was removed from the germ-line by breeding into 129SvEv and genotyping for the absence of Cre. This new mouse strain Tbx5 LDN/+ was bred 4 generations into 129SvEv before homozygous mice were generated. All methods performed on animals used in this study were approved by the Animal Care Committee of the Hospital for Sick Children.
In vivo electrocardiogram (ECG) telemetry collection
Twelve-week-old adult mice were anesthetized and EA-F20 telemetry device (Data Sciences International; St. Paul, MN) were implanted dorsally with electrodes in a lead II configuration. Mice were allowed to recover for 60 h postsurgery before ECG data were collected. Twenty measurements per ECG trace were collected during nocturnal activity (between 0:00 and 7:00) over at least two consecutive days. Data points were averaged to give a single value per mouse per parameter value examined. P wave width, P wave amplitude, PQ interval duration, QRS interval duration, QRS wave amplitude, ST interval duration, and heart rate were measured.
Magnetic resonance imaging (MRI) and optical projection tomography (OPT)
Mice were fixed for whole-body MRI by ultrasound guided left-ventricular catheterization as previously described (Zhou et al., 2004) . MR images were subsequently obtained with a 40-cm bore, 7-T magnet (Magnex Scientific, Oxford, UK) operated by a UnityINOVA console (Varian NMR Instruments, Palo Alto, CA). We used a conventional three-dimensional spin-echo sequence with the following parameters: 300ms repetition time, 10ms echo time, (28 × 28 × 120) mm 3 field-of-view, and 420 × 420 × 1800 imaging matrix. Total imaging time was 14.7h.
Optical projection tomography (OPT) was performed essentially, as described (Sharpe et al., 2002) , on embryos fluorescently labeled by in situ hybridization against Actc and Mybpc3 ( Lickert et al., 2004) . Visualization and manipulation of OPT data were performed with Amira 3.0 (Mercury Computer Systems Inc. Chelmsford, MA).
In situ hybridization
Whole-mount in situ hybridization was preformed according to standard protocols. Section in situ hybridization on paraffin sections was performed using modifications of the whole-mount in situ hybridization protocol.
Microarray analysis
Total RNA was isolated by TRIzol (Invitrogen, Carlsbad, CA) extraction from 14 to 20 pooled E11.5-E12.0 hearts and hybridized to Affymetrix MOE430A and MOE430B chips according to manufacturer's protocol. To reduce strain variations, the mice used for this experiment were kept in the same genetic background (50% 129SvEv, 50% Black Swiss). Three chip sets were run for RNA isolated from wild-type hearts, 3 for Tbx5 lox/+ and 4 for Tbx5
. Statistical comparisons of chip data were performed using GC-Robust Multichip Analysis (ArrayAssist V2.6.1642.30743; Iobion Informatics, Toronto, CA.) (Irizarry et al., 2003; Wu and Irizarry, 2004) with variance correction using two-tailed unpaired t tests against wild-type chips. A probe-set expression was considered altered if it had a P < 0.05 vs. wild type (unless stated otherwise). Hierarchical clustering was performed using SpotFire DecisionMaker software (Somerville, MA).
Quantitative real-time PCR
Total RNA was isolated from either whole embryos (E8.5) or isolated cardiac tissue (E12.5) using TRIzol reagent. Quantitative real-time PCR was performed using TaqMan probe sets (Applied Biosystems). Expression data were analyzed using the ΔΔCT method (Livak and Schmittgen, 2001) . GAPDH was chosen as a control gene. The network represented in Fig. 9 was created using Biotapestry (Ver. 0.96.0) available at http://labs.systemsbiology. net/bolouri/software/BioTapestry/.
MULAN multispecies alignment
The mouse DNA sequence 25kb upstream and 15kb downstream (or until the start of the adjacent gene) of genes identified on microarray and confirmed altered in Tbx5 del/+ mutants using either quantitative real-time PCR or in situ hybridization were entered into the multisequence local alignment tool MULAN (http://mulan.dcode.org; Ovcharenko et al., 2005) along with the homologous sequences from the rat, dog, and human genomes (where available) to identify evolutionarily conserved domains likely to contain conserved transcription factor binding sites. Once the genomic regions were aligned, multi-TF transcription factor binding site analysis was performed using a predefined matrix similarity of 0.85 to the PWMs shown in Fig. 8A . Two adjacent Tbx5 sites or a Tbx5 site adjacent to an Nkx2.5 site separated by less than 500bp was considered to be clustered. A Tbx5-insensitive gene is defined as a gene altered only in Tbx5 del/del or Tbx5 lox/lox mutants. A Tbx5-independent gene is defined as a gene known not to be altered in any Tbx5 mutant.
Results
Identification of a Tbx5 hypomorphic allele
Previous work has shown that aberrant splicing into a neomycin resistance cassette (Neo r ) contained within the coding region of an active gene can result in the reduction or complete inactivation of gene expression (Meyers et al., 1998;  , and Tbx5 LDN/LDN (bottom bands). (C) Quantitative real-time PCR analysis of Tbx5-exon 3 expression from either whole embryo lysate at E8.5 or isolated hearts at E12.5. Each mutant is normalized to its respective wild-type control. (D) Quantitative real-time PCR examining activity at the Tbx5 locus by examining expression of Tbx5-exon 1 containing mRNA isolated from E12.5 hearts showing increased activity from the Tbx5 del allele. *P < 0.05 versus WT. Xu et al., 2001) . The Tbx5 lox allele (Fig. 1A) contains a Neo r used for embryonic stem cell selection (Bruneau et al., 2001) . We hypothesized that Tbx5 lox might be a hypomorphic allele. Indeed, we could not recover live born Tbx5 lox/lox mice from crosses of Tbx5 lox/+ animals (see below). To test whether aberrant splicing was occurring in transcripts made from the Tbx5 lox allele, primers were designed in exon 1 and the 3′ end of Neo r (Supplemental Figure 1) , and potential hybrid mRNAs containing both Neo r and Tbx5 sequences were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) (Fig.  1B) . Two aberrantly spliced transcripts were seen in Tbx5 lox/lox samples, in addition to normal Tbx5 mRNA. Sequencing of these products confirmed erroneous splicing of normal Tbx5 transcript after exon 2 into the Neo r cassette. Both aberrant amplicons introduce stop codons into the primary Tbx5 transcript shortly after splicing into Neo r and would lack sequence encoding the T-box DNA binding motif of Tbx5; they are therefore presumed inactive. Alternative transcripts are absent in the wild-type control.
Selective removal of the Neo r cassette created the new allele Tbx5 LDN , which retains functional loxP sites flanking Tbx5 exon 3 (Fig. 1A) . RT-PCR from Tbx5 LDN/LDN RNA extracted at E10.5 shows only Tbx5 mRNA with no alternatively spliced mRNA and thus is analogous to wild type (Fig. 1B) . Tbx5 LDN/LDN mice are viable and live for more than one year.
Allelic series created by conditional allele of Tbx5
Both Tbx5 lox and Tbx5 del alleles express mRNA containing Tbx5 exons 1 and 2 but not exon 3. To quantitate levels of wild-type Tbx5 mRNA production in mutant backgrounds, primers were designed across the exons 2-3 boundary to specifically amplify functional exon 3-containing Tbx5 mRNA (Supplemental Figure 1) . Quantitative real-time (qRT)-PCR was performed on RNA isolated from E8.5 embryos at the linear heart tube stage (before homozygous mutants die) and on RNA isolated from E12.5 hearts at the stage prior to cardiac septation in heterozygous mutants (Fig. 1C) . The average amount of functional Tbx5 transcripts in Tbx5 lox/+ mice is similar at E8.5 (78 ± 1% of WT) and E12.5 (67 ± 10% of WT) (P = N.S.). In contrast, Tbx5 del/+ embryos express 30 ± 3% wild-type Tbx5 levels at E8.5 (P < 0.005 vs. WT), and expression increases to 55 ± 11% by E12.5 (P < 0.06 vs. E12.5 Tbx5 lox/+ ; P < 0.005 vs. WT). Tbx5 lox/lox embryos at E8.5 have 22 ± 1% functional Tbx5, suggesting that splicing variants account for approximately 80% of all transcripts from the Tbx5 lox locus. No exon 3-containing Tbx5 transcripts were detected from any of the Tbx5 del/del embryos examined (n = 8). Reduced expression from the Tbx5 lox allele creates an allelic series based on decreasing dosage of Tbx5 (from highest Tbx5 expression to lowest:
. To confirm that the observed decreases in Tbx5 expression were due to changes in the level of functional mRNA and not merely inactivity at the Tbx5 locus, qRT-PCR was performed using primers designed to amplify Tbx5 exon 1-containing mRNA (expressed from both endogenous and mutant Tbx5 alleles (see Supplemental Figure 1 ) to measure total activity from the Tbx5 locus at E12.5 (Fig. 1D) . Similar activity levels were observed between Tbx5 lox/+ embryos and the two wildtype strains. Unexpectedly, however, Tbx5 del/+ embryos showed a statistically significant increase in Tbx5 exon 1-containing mRNA over its strain-matched wild-type control (183 ± 58% vs. 100 ± 37%; P < 0.005). As this increased activity was not accompanied by increased Tbx5 exon 3 mRNA, we conclude that transcriptional activity was only increased from the null allele, which could suggest that the creation of the Cre-induced null allele removes a negative regulatory element and leads to a selective increase in this allelic variant of Tbx5.
Congenital heart defects in Tbx5 hypomorphic heterozygous mice
Crosses of Tbx5
lox/+ (129SvEv background) and wildtype 129SvEv mice yielded 42% Tbx5 lox/+ pups (76 of 180 examined; P < 0.05) at weaning suggesting that approximately 27% of Tbx5 lox/+ mice died prior to weaning. This phenotype is considerably milder than that seen in Tbx5 del/+ mice, which show greater than 90% perinatal death in a 129SvEv background (Bruneau et al., 2001) , and 59% perinatal death in a Black Swiss outbred background (36 Tbx5 del/+ pups of 124 mice alive at weaning (P < 0.001 altered from the 50:50 expected ratio). In comparison, Tbx5 LDN/+ mice survived to weaning in Mendelian proportions (65 Tbx5 LDN/+ mice of 122 examined at weaning; P = N.S.) and lived for more than 1 year afterwards.
Cardiac defects in surviving Tbx5 lox/+ mice were assessed at 12weeks of age by closed-chest magnetic resonance imaging ( Figs. 2A-C LDN/+ mice at 12weeks of age was examined using ECG telemetry over a 2-day period. A statistically significant increase in PQ-interval duration was measured in Tbx5 lox/+ hearts with respect to 129SvEv wild-type mice (37.1 ± 2.5 ms, n = 5 vs. 32.6 ± 0.7, n = 4, respectively; P < 0.01), indicative of first degree atrioventricular (AV) block (Table 1 ). This block is significantly less severe than that seen in Tbx5 del/+ mice (40.1 ± 1.3 ms, P < 0.05 vs. Tbx5 lox/+ ; P < 0.0002 vs. wild type). No other significant differences were observed for any other measurements. In addition, continuous monitoring of Tbx5 lox/+ mice over 48h showed sporadic electrophysiological anomalies, including occurrences of ventricular tachycardia, sinus rhythm with premature atrial complexes, secondary degree AV block and sinoatrial (SA) pauses (Figs. 2D-G) similar to those previously reported in Tbx5 del/+ mice (Bruneau et al., 2001 ).
Defects in heart formation in Tbx5 homozygous hypomorphic embryos
Tbx5
lox/lox mice were growth arrested at E9.5 and died before E11.5 (Fig. 3A) . Tbx5 lox/lox hearts at E8.5 had a hypoplastic left ventricle (LV) and sinoatrial structures (primitive inflow track and atria) whereas the right ventricle (RV) and outflow track continued to develop, characteristic of Tbx5 del/del heart development at the same stage (Figs. 3B-D). Optical projection tomography (OPT) imaging of E9.5 Tbx5 lox/lox mutants illustrated that heart development was arrested at E9.0 (Figs. 3E-M). Although Tbx5 lox/lox hearts had begun to loop, both atrial and ventricular structures were hypoplastic, lacking the left/right distinctions that are normally apparent at this stage. By comparison, E9.5 Tbx5 del/del hearts had a single columnar ventricle projecting from the chest cavity, previously demonstrated to be outflow tract and RV (Bruneau et al., 2001 ), whereas posterior structures (atria and LV) were severely hypoplastic. By E10.5 (Figs. 3N-V), clear distinctions between the four chambers of the wild-type heart were evident, and the atrial septum and cardiac cushions were beginning to form. In contrast, Tbx5 lox/lox hearts still had a tube-like atrium and single ventricle. A groove had now appeared that bisects the tube-like atrium (Fig. 3S) . A separation between the two halves of this atrial tube was evident ( Fig. 3V ) coincident with the initial stages of separation of the common atrium into left and right atria. No live Tbx5 del/del mutants have ever been recovered at E10.5, supporting our observations that Tbx5 lox/lox embryos have less severe defects in heart formation than Tbx5 del/del embryos.
Differential sensitivity of downstream genes to Tbx5 levels
Haploinsufficiency of Tbx5 results in dramatic changes in gene expression. We have previously shown that expression of Gja5 (encoding connexin 40) was reduced by 90% in hearts of Tbx5 del/+ mice, whereas expression of Nppa (encoding atrial natriuretic factor) was also decreased, albeit less dramatically (Bruneau et al., 2001) . In Tbx5 null embryos, decreased Gata4, Myl2, and Irx4 was observed (Bruneau et al., 2001) . Expression of these genes was assessed in our allelic series. It would be expected that mice with lower levels of Tbx5 expression would display a proportional reduction in cardiac differentiation marker expression. However, changes in expression were not uniform across all genes examined. Rather, we observe that although the expression of some genes such as Irx4 (Fig. 3A) and Gata4 (Fig. 4B ) was significantly reduced in Tbx5 lox/lox embryos, expression of Myl2 (Figs. 3B-D) was unchanged compared to wild-type littermates. Similarly, Nppa expression was not altered in E9.5 Tbx5 lox/+ embryos, whereas its expression was reduced in Tbx5 del/+ mice, as well as expanded across the interventricular septum. Such differences are manifest not only in changes throughout the entire heart but also in changes in expression within certain tissue types: Gja5 expression was significantly reduced in the ventricles of Tbx5 lox/+ embryos at E9.5, whereas atrial expression of Gja5 was maintained closer to wild-type levels (Fig. 4C ).
Gene expression profiling identifies Tbx5 dosage-sensitive genes
The data presented above draw comparisons between distinct populations of mice subdivided on the basis of genotype to show a correlation between CHD severity and Tbx5 dosage. However, subtle distinctions in phenotype are seen between individuals within a given subgroup due in part to variable Tbx5 expression in genetically identical mice (Fig. 5A ). Along this continuum of Tbx5 expression, it should be possible to differentiate genes that are highly sensitive to minor perturbations in Tbx5 (whose expression would be affected in both mild (Tbx5 lox/+ ) and severe (Tbx del/+ ) HOS cases) from those that are not as sensitive (and are therefore only affected in a subset of severe HOS cases). To this end, microarray analysis was performed using RNA isolated from pooled E11.5-12.0 embryos (WT, Tbx5 lox/+ , and Tbx5 del/+ ) in order to assess the sensitivity of different genetic pathways to varying dosages of Tbx5. To minimize strain-specific variation, all embryos were of a mixed background (50% 129SvEv/50% Black Swiss), and pools of 14-20 hearts further minimized individual variation due to strain or minor staging differences. Affymetrix MOE430A and MOE430B chips were used to analyze the expression over 45,265 Unigene clusters (n = 3 WT pools, 3 Tbx5 lox/+ pools, and 4 Tbx5 del/+ pools). After applying GC-Robust Multichip Analysis (GC-RMA), we identified 177 genes as having significantly altered gene expression: 94 of these genes are significantly altered in both Tbx5 lox/+ and Tbx5 del/+ mice (these genes represent highly sensitive Tbx5 gene targets, likely to be affected in all HOS patients), whereas the other 83 showed changes only in Tbx5 del/+ mice (these genes represent moderately sensitive gene targets, likely altered in only a subset of HOS patients). Of the initial 177 genes, only 98 showed strong changes in expression (greater than log 2 = ±0.3: defined as the minimum threshold of expression needed for independent validation by quantitative real-time PCR in our hands) (shown in Fig. 5B ). Among these 98 genes is Gja5, a direct target of Tbx5 that is known to be affected by Tbx5 haploinsufficiency (Bruneau et al., 2001) . Furthermore, because changes in expression of downstream targets are expected to be small, we also looked at those hits with slightly higher P values (0.05 < P < 0.10) to look for obvious cardiac genes potentially falsely eliminated by the stringent GC-RMA screen. We noted that the cardiac transcription factor genes Hand1, Irx2, and Shox2, the putative Wnt antagonist gene Dkk3, and the signaling molecule Slit2 were measured as having downregulated expression (expression changes >log2 = ±0.3) in both Tbx5-lox/+ and Tbx5 del/+ mice just short of the P < 0.05 cutoff (P = 0.0513, 0.0565, 0.0603, 0.0785, 0.0961, respectively, vs. WT). Given that all five genes are expressed in the heart, and may be involved in pathways related to Tbx5 function, we included them as putatively downregulated pending further experimentation, bringing the number of gene altered in Tbx5 del/+ hearts to 182 and the number of highly sensitive genes to 99.
Classification of the 182 microarray genes into gene ontology (GO) categories revealed predominant downregulations of expression of transcriptional regulators (22%) and signal transduction molecules (14%), whereas metabolic genes were predominantly increased (18%) (Fig. 5C ). By comparison, classification by GO annotation across the entire 45,290 probe set database showed that transcriptional regulation and signal transduction are only represented at a rate of 5.8% and 4.4%, respectively. Whereas highly sensitive Tbx5-regulated genes account for only 99 of 182 genes altered in Tbx5 del/+ mice, the relative ratios between functional classes of genes affected were maintained, suggesting that no single functional class of gene is more sensitive to changes in Tbx5 dosage (Tables 2 and 3) .
To independently confirm changes in expression of genes identified above, we used whole-mount in situ hybridization at E10.5 and section in situ hybridization at E11.5 to screen for Tbx5 lox/lox embryos at E8.5 (C) have hypoplastic left ventricle (LV) and sinoatrial structures (primitive inflow track and atria) whereas the right ventricle (RV) and outflow track continue to develop, characteristic of Tbx5 del/del heart development (D). Myl2 expression is maintained in Tbx5 lox/lox embryos (blue) whereas it is undetectable in Tbx5 del/del embryos. (E-M) Surface-rendered views of OPT on E9.5 WT, Tbx5 del/del , and Tbx5 lox/lox embryos; heart is red, embryo is translucent white. E9.5 Tbx5 del/del embryo outflow tract growth continues whereas LVand atrial structures are almost non-existent (Bruneau et al., 2001) . By comparison, Tbx5 lox/lox hearts have more developed posterior cardiac structures (H-J). Inner lumen of the hearts (yellow) are rendered in panels E-G. (K-M) Virtual sections through hearts shown in panels E-G. (N-V) OPT images of E10.5 Tbx5 lox/lox hearts compared to wild type. Tbx5 lox/lox hearts still have a tube-like atrium and single ventricle. A groove has appeared that bisects the tube-like atrium (white arrows in panel P). (Q-S) Inner lumen of hearts (yellow) are rendered in panels N-P. Examination of the cavity below the groove seen in Fig. 3P shows a physical separation between the two halves of this atrial tube. (T-V) Virtual sections through hearts shown in panels N-P. Virtual section through the heart in panel S (plane parallel to the green line) shows the development of a connection between the two halves of the single atria. changes in expression of 12 putative downstream targets (2610024A01Rik, Agpat3, Ddx52, Dkk3, Eya1, Fbx032, Hand1, Hk1, Slit2, Tbx3, Vsnl1, Wisp1) in Tbx5 del/+ mutants. All 12 genes were expressed in the heart, and 8 of these (2610024A01, Ddx52, Dkk3, Eya1, Fbx032, Hk1, Vsnl1, Wisp1) were also expressed in the limbs. Obvious changes were seen in the expression of 7 genes (Dkk3, Fbxo32, Hand1, Hk1, Slit2, Tbx3, Wisp1), consistent with that seen on the microarray (Fig.  6 ). In addition, expansion of Wisp1 expression was noted across the interventricular septum (Fig. 6F) . Changes in the expression of Agpat3 (Fig. 6A ) and Ddx52 (data not shown) were noted opposite to that reported by microarray. The remainder of genes showed no appreciable change in expression by in situ.
Gene expression kinetics
A more sensitive screen of the microarray data was performed with qRT-PCR by examining the expression of 17 genes using RNA from individual E12.5 hearts; 12 genes showed altered expression consistent with the microarray data ( Fig. 7A; Supplemental Figure 2 ). Additionally, we also quantitated expression of the transcription factors Hand1, Shox2, Irx2, and Irx1-expressed in an overlapping domain with Irx2 in the intraventricular septum (Christoffels et al., 2000) and found all were significantly decreased in Tbx5 del/+ and Tbx5 lox/+ hearts. Tbx2, expressed in an overlapping pattern with Tbx3 in the atrioventricular canal (Gibson-Brown et al., 1998; Habets et al., 2002; Yamada et al., 2000) , was not increased in mutant hearts (Supplemental Figure 2) . Expression of Myl2 and Irx4 (genes known to be downregulated exclusively in Tbx5 del/del embryos) were used as negative controls and showed no statistically significant changes in expression in either heterozygous mutant. In total, we independently confirmed expression changes in 17 of 23 genes (74%) consistent with the changes reported by the microarray screen.
When changes in gene expression (δx) were examined as a function of Tbx5 mRNA levels (δd), several different expression kinetics were observed, most likely indicative of varying modes of gene regulation (Figs. 7B-J) . At one extreme, δx/δd for Gja5 expression remained constant at all Tbx5 levels examined (R 2 = 0.77), as reflected by the linear relationship between Tbx5 dosage and Gja5 expression. In comparison, the δx/δd of Vsnl1, Shox2, and Ddc was constant at concentrations of Tbx5 near 100% but rapidly changed at lower Tbx5 dosages, consistent with a prompt loss in either gene activation (Vsnl1, Shox2) or in gene repression (Ddc). Tbx3 exhibited the most dynamic changes in expression, best described by a sinusoidal curve (R 2 = 0.73) such that the δx/δd was constant at high and low concentrations of Tbx5 but changed rapidly between 50% and 90% WT Tbx5 mRNA levels, consistent with a thresholdmediated method of gene expression control. Examination of Irx4 ( Fig. 5G ; R 2 = 0.007) or Myl2 (R 2 = 0.003) expression showed no obvious change in the general level of expression of with decreasing Tbx5 dosage within the range of Tbx5 mRNA levels examined (δx/δd ≈ 0).
Of the 16 genes examined in Tbx5 lox/+ , 6 showed greater expression changes in hypomorphic samples than in Tbx5 del/+ hearts, albeit in only one case (Brd8) was this difference statistically significant (P < 0.0001). By plotting the expression of these genes, more complex interactions were observed. For instance, Brd8 expression was increased in Tbx5 del/+ hearts while it was decreased in Tbx5 lox/+ hearts leading to an inverted bell-shaped curve. In contrast, Cdo1 expression could not be described by a trend line but rather appeared to separate into two distinct clusters, one higher than another. Cardiac expression of Fbxo32 showed a clearly linear relationship in wild-type and Tbx5 lox/+ samples and in a subset of Tbx5 del/+ hearts. However, at the lower extreme, some heterozygous null hearts begin expressing more Fbxo32. An important caveat of these analyses is that difference in gene expression measured from whole E12.5 hearts may not reflect dynamic spatiotemporal changes in gene expression, such as the decreased but expanded expression of Nppa, and hearts by microarray analysis; *P < 0.05. Irx4 and Myl2 are negative controls. (B-J) Profiles of gene expression in individual hearts in relation to Tbx5 mRNA levels reveal different kinetic interactions from linear (Gja5) to sinusoidal (Tbx3). The expression of genes such as Cdo1 and Fbxo32 appear to be differentially expressed within individual hearts of the same genotype, suggesting that compensatory mechanisms might be adjusting gene expression to try and compensate for the loss of Tbx5. 100% is defined as the average of wild type on both axes. furthermore, changes in distinct regions of the heart might be masked by the absence of change elsewhere in the heart. It is also possible that the differential expression of some genes may be reflective of decreased growth or failed differentiation of certain cardiac structures, which cannot be assessed by measuring gene expression. Therefore, these 182 gene clusters do not represent an exhaustive list of Tbx5-regulated genes but rather are a subset of Tbx5 dosage-sensitive genes, some of which may be causative in the etiology of HOS. Nonetheless, it is clear that dosage of Tbx5 is key to regulation of several genes in complex and dynamic patterns.
Tbx5 binding site clusters in dosage-sensitive genes
Tbx5 binds a consensus DNA sequence loosely defined as A/G/TG/AGTGNNA. Using a position weight matrix (PWM) based on all published T-box binding sites (Fig. 8A) , an in silico Fig. 8 . Frequency and positioning of T-box and Nkx2.5 transcription factor binding sites surrounding Tbx5-sensitive genes. (A) High-quality position weight matrices for T-box binding sites (TBEs) and Nkx2.5 binding sites (NBEs) were used to define transcription factor binding sites. (B) The frequency of TBEs either alone or as clustered sites tends to increase in the genomic region surrounding Tbx5 dosage-sensitive targets (±standard error). (C-E) Genomic positioning of TBEs and TBE/ NKE clusters on DNA surrounding both Tbx5-sensitive genes (C), and Tbx5-insensitive (D) and Tbx5-independent genes (E) appear dispersed both up-and downstream and within intronic regions, suggesting that TBE position by itself is not predictive of Tbx5 dosage sensitivity. Alignments were performed between mouse and dog (α), mouse and human (β), and mouse and rat (δ).
analysis of potential genomic regulatory regions, both around and within the validated set of Tbx5 dosage-sensitive genes, was performed using MULAN and MultiTF to examine the frequency and position of evolutionarily conserved T-box binding elements (TBEs) between mouse, human, rat, and dog. In addition, as synergy with Nkx2-5 may be a key mechanism for dosage sensitivity, a similar analysis was performed to identify Nkx2.5 binding sites (NBEs) using the PWM shown in Fig. 8A . A set of 9 myocardial genes insensitive to Tbx5 dosage (defined as not altered on the Tbx5 del/+ microarray) were used as a control set to determine the baseline frequency of randomly positioned TBEs/NBEs within a given genomic region.
The positioning of lone TBEs or TBE/NBE clusters within the DNA surrounding dosage-sensitive targets reveals no obvious spatial similarities between genes (Fig. 8C) . Transcription factor binding sites surrounding Tbx3, as an example, are located exclusively upstream of the gene and consist of numerous TBEs and two clustered sites separated by greater than 15kb. In contrast, DNA binding sites near Irx2 are almost exclusively located within the 3′ UTR and downstream genomic region where several clustered sites appear to be tightly grouped. Irx1 and Hand1, in comparison, have both upand downstream clustered sites, whereas Shox2 has numerous dispersed sites within intronic DNA. Similarly, when transcription factor binding sites were examined in the set of Tbx5-insensitive/independent genes (Figs. 8D and E), no obvious pattern in binding site position was noted, although the number of sites (both lone and clustered sites) did seem to decrease (see below). This analysis suggests that the positional location of TBEs and NBEs is not predictive of a gene's sensitivity to Tbx5 dosage. It should be noted, however, that this search is not exhaustive of all possible Tbx5 interactions (Tbx5 has been shown to physically interact and synergize with GATA4 for example; Garg et al., 2003) and is limited to the examination of only 25 kb upstream and 15 kb downstream surrounding the genes of interest.
The number of TBEs and clustered TBE/NKE sites were quantitated in both our highly sensitive (n = 17) and nonsensitive (n = 9) group of genes (Fig. 8B) . Keeping in mind that it is unlikely that all 17 analyzed Tbx5-sensitive genes are direct Tbx5 targets, our analysis reveals that Tbx5-sensitive genes have a trend towards having greater numbers of TBEs within the genomic region flanking them than genes in the non-sensitive control group (7.4 ± 3.4 vs. 2.4 ± 0.5). In addition, the number of clustered TBE/TBE and TBE/NKE sites also tends to be higher in the sensitive population (1.0 ± 0.7SE vs. 0.1 ± 0.1SE and 2.2 ± 1.0SE vs.0.3 ± 0.2SE, respectively). Therefore, increased TBE density, either alone or in close association with Nkx2.5 sites, may be a potential indicator of Tbx5 dosage sensitivity.
Discussion
We have shown, using a Tbx5 allelic series, that the developing mouse heart is exquisitely sensitive to altered dosage of Tbx5 (summarized in Table 1 ). By gene expression profiling, we have uncovered subsets of genes downstream of Tbx5 that may be involved in regulating CHD severity due to Tbx5 haploinsufficiency. The rheostatic regulation of cardiac gene expression by Tbx5 indicates that the variable expressivity of TBX5 mutations in humans is likely to be due to threshold regulation of differentially sensitive genes.
Tbx5 dosage and cardiac morphogenesis
We observed a very close correlation between Tbx5 dosage and the severity of defective cardiac morphogenesis. Hypomorphic heterozygous mice (Tbx5 lox/+ ) consistently had milder conduction system disease and a concurrent dramatic increase in survivability over the heterozygous null mice. Likewise, homozygous hypomorphs (Tbx5 lox/lox ) had better developed cardiac structures and survived one day longer than Tbx5 del/del null embryos. These results illustrate that even slight differences in Tbx5 dosage (of <15%) during development can lead to dramatic changes in phenotype.
In examining the differences observed between Tbx5 hypomorphic and null mutants, we observed a large initial disparity in Tbx5 dosage between heterozygous mutants. Interestingly, this difference was observed at E8.5, at a time when Tbx5 is expressed as an anterior-posterior gradient in the linear heart tube with strongest expression in posterior regions destined to become atria (Bruneau et al., 1999) . Furthermore, it has been suggested that Tbx5 might bind its own promoter and induce its own expression in vitro (Sun et al., 2004) . If Tbx5 does regulate its own expression in vivo, small differences in initial Tbx5 dosage due to haploinsufficiency may result in delayed establishment of this anterior-posterior event, thus postponing or precluding crucial patterning or differentiation events within the heart.
Differential sensitivity of downstream genes to the Tbx5 dosage gradient
Increased severity of CHDs due to decreased Tbx5 levels correlated with critical changes in gene expression, and translated to altered survival. It is likely that genes that are highly sensitive to perturbations in Tbx5 levels are associated with fundamental disease-associated processes, whereas those that are only moderately affected by Tbx5 haploinsufficiency perhaps have roles in modulating the severity of the HOS-associated defects. In human populations, this might be reflected in the large variation that exists in families with HOS or other CHDs. Modifier genes might therefore be involved in modulating Tbx5 expression from the remaining wild-type allele in response to haploinsufficiency or may act as genetic amplifiers to enhance expression of specific Tbx5 targets.
Dynamics of gene regulation by Tbx5
Examination of expression dynamics for genes regulated by Tbx5 illustrates distinctly different responses to decreasing Tbx5 dosage. The expression of a subset of genes can be defined as a direct function of the dosage of Tbx5 as would be expected if they represent direct Tbx5 targets, as has been shown for Gja5 (Bruneau et al., 2001) . In contrast, expression of other genes can change rapidly at lower levels of Tbx5, and in some cases gene expression changes were observed to exhibit stochastic expression properties. The regulatory modules that control the Tbx5 responsiveness of the former subset of downstream genes must be regulated by more complex interactions between Tbx5 and other positively or negatively acting transcription factors, whereas the latter group appear only Tbx5 dose-responsive in a subset of the same genotype, most likely due to the action of additional genetic modifiers that might independently adjust gene expression to compensate for the loss of Tbx5. Deciphering the nature of these dynamic transcriptional rheostats in model organisms has to date yielded conflicting information, and thus will be difficult to resolve. Together these data indicate that Tbx5 can regulate downstream genes via an array of independent mechanisms, some of which will include direct DNA binding, and others via indirect mechanisms that may involve complex regulatory networks.
Tbx5 regulates transcription factor networks in the heart
Several of the genes identified by gene expression profiling are transcription factors or are involved in transcriptional regulation, which places Tbx5 upstream of numerous different transcriptional cascades in the developing heart. For example, the transcriptional repressor Tbx3 is significantly reduced in the Tbx5 mutant hearts. Tbx3 cardiac expression is seen from E8.5 onward in the myocardium that will become cardiac conduction system and is maintained throughout development in the sinoatrial and atrioventricular nodes as well as in the cardiac bundle branches (Hoogaars et al., 2004) . Tbx5 and Tbx3 compete for binding sites on the promoters of Gja5 and Nppa (two direct targets activated by Tbx5) in dosage-dependent manners (Hoogaars et al., 2004) . Our results suggest that Tbx5 normally enhances Tbx3 expression, thus creating a regulatory feedback circuit whereby Tbx5 sustains the expression of Tbx3, which in turn locally counters the activation of certain genes by Tbx5 within the cardiac conduction system (Fig. 9) . That the regulation of Tbx3 is sensitive to Tbx5 dosage allows for the creation of sharp boundaries of expression upon reaching a given dosage of Tbx5 thus ensuring the correct balance between activator (Tbx5) and repressor (Tbx3) is maintained. This reveals a crucial and very fine genetic interaction between T-box transcription factors in the developing heart, which has evolved very specifically to preserve accurate spatiotemporal transcription of cardiac genes even in the face of genetic disturbances. The architecture of such a genetic feedback loop where transactivator and transrepressor compete for binding to common DNA binding sites has been shown to induce rapid dosage-dependent switching behaviour in gene expression in vitro (Rossi et al., 2000) .
The transcriptional coactivators Yap1 and Taz are also both downregulated in Tbx5 mutant mice. It has been shown recently that both Yap1 and Taz interact as part of the Tbx5 transcriptional machinery to potently promote Tbx5-dependent transcription (Murakami et al., 2005) . It has been suggested that this coactivation may occur through interactions between Taz and histone acetyltransferases (HATs) (Murakami et al., 2005) . It is possible therefore that the differential sensitivity of downstream genes to Tbx5 dosage is due in part to varying degrees of histone modification of Tbx5 target gene promoter sequences. Minor perturbations in the level of Tbx5, combined with further decreases in the expression of both Taz and Yap1 would render genes in highly deacetylated regions of chromatin less accessible to Tbx5 activation, whereas genes situated less condensed regions of chromatin would be less sensitive to decreased HAT recruitment and would therefore remain transcriptionally active.
In addition to disrupting transcriptional networks, Tbx5 haploinsufficiency also alters numerous signaling cascades in the developing heart. The secreted signaling molecule Slit2 that we show to be predominantly expressed in ventricular trabeculae is also downstream of Tbx5 in the heart. Slit2, Fig. 9 . This gene regulatory network is implied by microarray and real-time data wherein the regulation of Gja5 and Nppa occur via interactions between Tbx5 and Tbx3 with Nkx2.5. originally identified as a repulsive cue during axonal pathfinding, has also been shown to act as a potent chemorepellant during cell migration (Wu et al., 2001) . Additionally, Drosophila slit has recently been shown to act as a guide to align myocardial cells converging at the midline during heart tube closure in fly (Qian et al., 2005) . The expression of Slit2 on either side of the interventricular septum may form a repulsive corridor that might help position the location of septal outgrowth.
Tbx5 mutant mice also show disruptions in the expression of genes involved in inhibition of the Wnt/β-catenin signaling pathway (Cxxc4, Dkk3). The balance between Wnts and their antagonists play a critical role in shaping the primary heart field during early cardiogenesis. Wnt/β-catenin signals emanating from the neural tube act as negative regulators of myocardial cell fate (Marvin et al., 2001; Tzahor and Lassar, 2001) . Wnt antagonists counterbalance these inhibitory signals and have been shown to play important roles in promoting cardiac mesoderm formation (Lickert et al., 2002; Marvin et al., 2001; Tzahor and Lassar, 2001) . Decreases in Cxxc4 and Dkk3 in Tbx5-deficient mice most likely would disrupt proper cell fate specification during heart development. Decreases in Gsk3β (involved in the Wnt-induced production of β-catenin) may partially compensate for loss of these important Wnt inhibitors while accounting for downregulation of Wisp1 (normally induced by Wnt1/β-catenin expression; Xu et al., 2000) . Expanded Wisp1 expression across the interventricular septum is also consistent with disrupted cellular specification.
T-box genes have been shown in vivo to interact in regulatory networks to carefully pattern specific tissues through synergistic and antagonistic interactions with other transcription factors (including but not restricted to other T-box transcription factors) in fish, worm, and mice (Goering et al., 2003; KoshibaTakeuchi et al., 2006; Pocock et al., 2004; Takeuchi et al., 2005) . Such regulatory networks of transcription factors ensure specificity of patterning and very fine regulation of output levels but also open up a large network to perturbed levels of the primary regulator, in this case Tbx5.
Conclusions
The dosage of Tbx5 communicates spatiotemporal information to cells within the early heart that is used to carefully orchestrate patterns of cardiac development and it is well established that decreases in Tbx5 dosage cause congenital heart defects. We have shown that there is a direct relationship between Tbx5 dosage during early heart development and the severity of concomitant heart defects. It is likely that such differences in Tbx5 dosage brought about due to slightly different genetic backgrounds and the effect of modifier genes account for the large variation in severity of HOS clinical presentation. Changes in the severity of CHDs are underpinned by differential sensitivities of downstream genes to varying levels of Tbx5. These differences represent variation in the underlying control elements that regulate the expression of these genes and are important to investigate as changes in these genes lead to a marked increase in survivability.
